A Multicenter, Randomized, Double-Blind, Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination Taken Orally for 8 Weeks in Adult Subjects with Essential Hypertension Who Are Inadequately Controlled on 16 mg Candesartan Cilexetil Monotherapy
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 25 May 2017
At a glance
- Drugs Candesartan cilexetil/nifedipine (Primary) ; Candesartan cilexetil
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Bayer; Bayer HealthCare
- 16 Dec 2016 This trial has been completed in Spain.
- 15 Dec 2016 This trial was completed in Germany (end date: 2016-09-28), according to European Clinical Trials Database.
- 01 Dec 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.